Physician profile
Simona Fikhman
NPI 1477979656
$11,927.72
in general payments reported to CMS, 2019-2025
31 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what 95% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $845 · 2022: $4,115 · 2023: $2,785 · 2024: $2,278 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,460 · Honoraria: $500 · Travel and Lodging: $7.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,460.30 |
| Honoraria | $500.00 |
| Travel and Lodging | $7.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $2,975.04 | 2021-2025 | Ilumya |
| Abbvie INC. | $1,250.58 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,144.12 | 2021-2025 | |
| Genzyme Corporation | $799.78 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $786.90 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $775.92 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $554.24 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $505.06 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $406.02 | 2021-2024 | Aklief, Epsolay, Oracea |
| Lilly USA, LLC | $394.64 | 2021-2025 | Ebglyss, Olumiant, Taltz |
| Janssen Biotech, INC. | $389.34 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $354.41 | 2023-2025 | Dupixent |
| Dermavant Sciences, INC. | $200.63 | 2022-2024 | Vtama |
| Incyte Corporation | $189.41 | 2022-2025 | Opzelura |
| Epi Health, LLC | $162.03 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $161.84 | 2021-2025 | Otezla |
| Revance Therapeutics, INC. | $155.74 | 2024 | Daxxify |
| Organon LLC | $140.10 | 2025 | Vtama |
| Pfizer INC. | $107.11 | 2021-2025 | |
| Journey Medical Corporation | $102.43 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $61.06 | 2023 | Sotyktu |
| Janssen Scientific Affairs, LLC | $60.00 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.37 | 2021-2024 | Siliq, Duobrii |
| Almirall LLC | $37.95 | 2025 | Klisyri |
| Botanix Sb INC | $34.66 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $33.21 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $24.73 | 2024 | Clear & Brilliant, Fraxel |
| Krystal Biotech INC | $24.44 | 2024 | Vyjuvek |
| Biofrontera INC. | $23.22 | 2025 | |
| Verrica Pharmaceuticals INC. | $18.81 | 2025 | Ycanth |
| Merz North America, INC. | $15.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simona Fikhman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.